Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The oral semaglutide pill for weight loss hit 100,000 new monthly prescriptions within just 2 months of its January 2026 launch — faster than any injectable rival. Crucially, it didn't cannibalize injectable semaglutide sales; instead, it appears to be pulling in new patients. The pill may be expanding the obesity treatment market for those who avoided needles or faced access barriers.
The obesity treatment landscape just got a major shake-up. A daily oral semaglutide pill launched in January 2026 hit 100,000 new monthly prescriptions in just 2 months — a pace that left its injectable counterparts in the dust. For comparison, injectable tirzepatide took 4 months to reach that milestone, and injectable semaglutide took a whopping 20 months.
What's especially notable: injectable semaglutide prescriptions didn't drop after the pill arrived. Total semaglutide prescriptions for weight loss actually rose, suggesting the pill is bringing in new patients — particularly those deterred by needles, cost, or access issues — rather than simply swapping out shots. By June 2026, combined semaglutide prescriptions were approaching (but hadn't yet surpassed) tirzepatide volumes.
Why it matters: Needle aversion and access barriers have long limited who gets treated for obesity. The pill's rapid uptake signals a potential expansion of the treated population — a meaningful shift for clinicians, payers, and public health alike.
